Diphyllobothriasis medical therapy

Jump to navigation Jump to search

Diphyllobothriasis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Diphyllobothriasis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT Scan

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Diphyllobothriasis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

slides

Images

American Roentgen Ray Society Images of Diphyllobothriasis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Diphyllobothriasis medical therapy

CDC on Diphyllobothriasis medical therapy

Diphyllobothriasis medical therapy in the news

Blogs on Diphyllobothriasis medical therapy

Directions to Hospitals Treating Diphyllobothriasis

Risk calculators and risk factors for Diphyllobothriasis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Kalsang Dolma, M.B.B.S.[2], Furqan M M. M.B.B.S[3]

Overview

Medical therapy is the primary modality of treatment for diphyllobothriasis. Drugs used for diphyllobothriasis include either praziquantel or niclosamide.

Medical Therapy

The medications used in the treatment of diphyllobothriasis are:[1][2]

Antimicrobial Regimen

The dose for empiric treatment of diphyllobothriasis is as follows:[1][2]

  • Diphyllobothriasis
    • 1.1 Adult
      • Preferred regimen (1): Praziquantel 5-10 mg/kg orally in a single-dose therapy.
      • Alternative regimen (1): Niclosamide 2 gm single dose orally for adults.
    • 1.2 Children
      • Preferred regimen (1): Praziquantel 5-10 mg/kg orally in a single-dose therapy.
      • Alternative regimen (1): Niclosamide 50 mg/kg (max 2 gm) orally once.

Mechanism of action

  1. Praziquantel
    • Oral praziquantel is available for human use in the United States. Praziquantel increases the permeability of the cell membrane towards calcium ions. This induces contraction of the parasites, resulting in paralysis in the contracted state.
  2. Niclosamide
    • Niclosamide inhibits the oxidative phosphorylation and anaerobic metabolism in the parasites.

References

  1. 1.0 1.1 "CDC - DPDx - Diphyllobothriasis".
  2. 2.0 2.1 Scholz T, Garcia HH, Kuchta R, Wicht B (2009). "Update on the human broad tapeworm (genus diphyllobothrium), including clinical relevance". Clin. Microbiol. Rev. 22 (1): 146–60, Table of Contents. doi:10.1128/CMR.00033-08. PMC 2620636. PMID 19136438.

Template:WH Template:WS